Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
vopimetostat + ERAS-0015
- Development stage
- Unknown
- Lead developer
- Tango Therapeutics
- Modality
- Molecular Glues → Targeted Protein Degraders (TPDs) → Small Molecules
- Administration
- Oral
01
Overview
Vopimetostat + ERAS-0015 is an investigational combination therapy comprising vopimetostat (TNG462), a next-generation PRMT5 inhibitor, and ERAS-0015, a pan-RAS molecular glue. Vopimetostat is designed to selectively target MTAP-deleted cancer cells by exploiting the accumulation of methylthioadenosine (MTA), which sensitizes these cells to PRMT5 inhibition. ERAS-0015 acts by recruiting cyclophilin A to RAS proteins, thereby inhibiting signaling across multiple RAS mutations and disrupting the MAPK/ERK and PI3K/AKT pathways. The combination is being developed under a clinical trial collaboration between Tango Therapeutics and Erasca to treat MTAP-deleted pancreatic cancer and RAS-mutant non-small cell lung cancer (NSCLC), aiming to provide synergistic anti-tumor activity by simultaneously blocking the RAS pathway and PRMT5.
- Other names
- vopimetostat and ERAS-0015
02
Targets
PRMT5 (Protein arginine N-methyltransferase 5)PPIA (Peptidyl-prolyl cis-trans isomerase A)HRAS (H-Ras protein)
Beyond the preview
Go deeper on vopimetostat + ERAS-0015.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on vopimetostat + ERAS-0015.